COMPASS Pathways acquires Intellectual property rights of Novel Psychedelics

COMPASS Pathways, a mental health enterprise that focuses on building accessible and innovative strategies to target mental health problems has purchased rights to use and replicate therapeutic psychedelics. These psychedelics belong to a specific line of drugs concocted and patented by Matthias Grill, the founder and chief of MiHKAL GmbH based in the Switzerlands. Dr Grill has been involved in psychedelic research since 15 years and has headed R and D departments of major pharmaceutical companies. He explains that the novelty lies in the formulations which are modified versions of older drugs. The patent rights also cover a range of prodrugs - these are inactive molecules metabolized by the body which go on to prove instrumental in the synthesis of active drugs. The leadership at COMPASS believes that the rights will help them create faster solutions to the ever mounting demands of mental healthcare.